FDA approves Biocon's Pebrilzo pertuzumab biosimilar for HER2-positive breast cancer

Biocon has secured US FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, expanding its oncology biosimilar portfolio while commercial entry remains subject to a patent settlement allowing launch from the third quarter of 2028.
Biocon announced on 16 November 2026 that the US Food and Drug Administration had approved Pebrilzo (pertuzumab-qcay), a biosimilar to Genentech's Perjeta, for HER2-positive breast cancer, marking the company's fifth oncology biosimilar approval in the United States.
Although the approval establishes a new regulatory milestone and a potential additional biosimilar treatment option, Biocon's global patent settlement with Genentech provides for the earliest licensed US commercial launch in the third quarter of 2028, meaning the decision does not constitute immediate market availability or evidence that Pebrilzo is clinically superior to the reference medicine.
Field | Content |
Article Type | Approvals |
Company | Biocon |
Product Brand Name | Pebrilzo |
Active Ingredient | Pertuzumab-qcay |
Product Classification | Biosimilar |
Reference Product | Perjeta |
Reference Product Company | Genentech |
Regulatory Authority | US Food and Drug Administration |
Announcement Date | 16 November 2026 |
Regulatory Decision | FDA biosimilar approval |
Regulatory Market | United States |
Therapeutic Area | Oncology |
Cancer Type | Breast cancer |
Molecular Subtype | HER2-positive |
Therapeutic Target | HER2 |
Biocon US Oncology Biosimilar Portfolio Position | Fifth oncology biosimilar |
Approval Status | Approved |
US Commercial Launch Status | Not yet launched |
Earliest Licensed US Launch | Third quarter of 2028 |
Launch Timing Basis | Global patent settlement with Genentech |
Patent Settlement Counterparty | Genentech |
Reference Medicine Comparison | Biosimilar to Perjeta |
Clinical Superiority Established | No |
Immediate US Commercial Availability | No |
What Happened | The FDA approved Biocon's Pebrilzo as a biosimilar to pertuzumab reference medicine Perjeta. |
Why It Matters | The approval expands the potential future range of biosimilar treatment options for HER2-positive breast cancer. |
Regulatory Significance | Adds another FDA-approved oncology biosimilar to Biocon's portfolio. |
Commercial Significance | Establishes regulatory readiness ahead of a planned US market entry permitted from the third quarter of 2028. |
Access Implications | Future commercial entry may introduce additional competition in HER2-targeted oncology treatment. |
Launch Clarification | FDA approval and commercial launch are separate milestones. |
Patent Clarification | The reported patent settlement sets the earliest licensed US launch timing. |
Key Takeaway | Pebrilzo has received FDA approval, but its earliest licensed US launch is scheduled for the third quarter of 2028. |
What to Watch | Commercial launch preparations, patent settlement implementation, market access, pricing and adoption after launch. |
Primary Source | Biocon |
Primary Source URL | https://www.biocon.com/biocon-gets-u-s-fda-approval-for-pebrilzo-pertuzumab-qcay-injection-a-biosimilar-to-perjeta-expanding-its-oncology-portfolio/ |
Submitted Source | Business Standard |
Submitted Source URL | https://www.business-standard.com/companies/news/biocon-secures-us-fda-approval-for-pebrilzo-its-fifth-cancer-biosimilar-126111600687_1.html |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


留言